Evidence map›Paper›PMID 37008199›Full record

ArticleAdvanced functional materials2022

Expanding Structural Space for Immunomodulatory Nucleic Acid Nanoparticles (Nanps) via Spatial Arrangement of Their Therapeutic Moieties.

Morgan Chandler, Lewis Rolband, M Brittany Johnson, Da Shi, Yelixza I Avila, Edward Cedrone, Damian Beasock, Leyla Danai, Elizabeth Stassenko, Joanna K Krueger and 4 more

Abstract read
In one paragraph

Article in Advanced functional materials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Morgan ChandlerNanoscale Science Program, Department of Chemistry, University of North Carolina at Charlotte, Charlotte, NC 28223, USA.
Lewis RolbandNanoscale Science Program, Department of Chemistry, University of North Carolina at Charlotte, Charlotte, NC 28223, USA.
M Brittany JohnsonDepartment of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC 28223, USA.
Da ShiNanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Yelixza I AvilaNanoscale Science Program, Department of Chemistry, University of North Carolina at Charlotte, Charlotte, NC 28223, USA.
Edward CedroneNanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Damian BeasockNanoscale Science Program, Department of Chemistry, University of North Carolina at Charlotte, Charlotte, NC 28223, USA.
Leyla DanaiNanoscale Science Program, Department of Chemistry, University of North Carolina at Charlotte, Charlotte, NC 28223, USA.
Elizabeth StassenkoNanoscale Science Program, Department of Chemistry, University of North Carolina at Charlotte, Charlotte, NC 28223, USA.
Joanna K KruegerNanoscale Science Program, Department of Chemistry, University of North Carolina at Charlotte, Charlotte, NC 28223, USA.
Jiancheng JiangDepartment of Mathematics, University of North Carolina at Charlotte, Charlotte, NC 28223, USA.
Jeoung Soo LeeDrug Design, Development, and Delivery (4D) Laboratory, Department of Bioengineering, Clemson University, Clemson, SC 29634, USA.
Marina A DobrovolskaiaNanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Kirill A AfoninNanoscale Science Program, Department of Chemistry, University of North Carolina at Charlotte, Charlotte, NC 28223, USA.

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
X-ray Scattering Technology CoreP30GM133893 · NIGMS · BROOKHAVEN SCIENCE ASSOC-BROOKHAVEN LAB · PI Vivian Stojanoff · 2019 to 2026
$38.6M
SMART NANPs: new molecular platform for communication with human immune system and modulation of therapeutic responsesR35GM139587 · NIGMS · UNIVERSITY OF NORTH CAROLINA CHARLOTTE · PI AFONIN, KIRILL A · 2021 to 2025
$1.8M
Characterization of various multifunctional nucleic acid nanoparticles and understanding their immunotoxicityR01GM120487 · NIGMS · UNIVERSITY OF NORTH CAROLINA CHARLOTTE · PI AFONIN, KIRILL A · 2017 to 2020
$1.5M
Neuron-specific nanotherapeutics for spinal cord injury repairR01NS111037 · NINDS · CLEMSON UNIVERSITY · PI LEE, JEOUNG SOO · 2019 to 2022
$1.3M
NCI NIH HHS 75N91019D00024NIGMS NIH HHS P30 GM133893NIGMS NIH HHS R01 GM120487NIGMS NIH HHS R35 GM139587NINDS NIH HHS R01 NS111037
6 · The paper itself

Abstract

Different therapeutic nucleic acids (TNAs) can be unified in a single structure by their elongation with short oligonucleotides designed to self-assemble into nucleic acid nanoparticles (NANPs). With this approach, therapeutic cocktails with precisely controlled composition and stoichiometry of active ingredients can be delivered to the same diseased cells for enhancing pharmaceutical action. In this work, an additional nanotechnology-based therapeutic option that enlists a biocompatible NANP-encoded platform for their controlled patient-specific immunorecognition is explored. For this, a set of representative functional NANPs is extensively characterized in vitro, ex vivo, and in vivo and then further analyzed for immunostimulation of human peripheral blood mononuclear cells freshly collected from healthy donor volunteers. The results of the study present the advancement of the current TNA approach toward personalized medicine and offer a new strategy to potentially address top public health challenges related to drug overdose and safety through the biodegradable nature of the functional platform with immunostimulatory regulation.

Indexed as

immunotherapynucleic acid nanoparticlesPBMCsSAXStherapeutic nucleic acids

Identifiers

PMID37008199
PMCPMC10065476

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.